|This Slide: #73 of 100|
Slide #73. Intrexon Corporation — Laboratory Operations from Codexis
Intrexon Corporation (XON)
Laboratory Operations from Codexis
Intrexon Corporation (NYSE: XON), a leader in synthetic biology, today announced that it has acquired state-of-the-art laboratory operations in Budapest, Hungary from Codexis, Inc., a developer of biocatalysts for the pharmaceutical and complex chemistry industries.
Intrexon is engaged in the field of synthetic biology, focusing on programming biological systems to alleviate disease, remediate environmental challenges, and provide sustainable food and industrial chemicals. Using its suite of technologies, Co. designs, builds and regulates gene programs, which are DNA sequences that consist of primary genetic components. A single gene program or a complex, multi-genic program is fabricated and stored within a DNA vector. Vectors are segments of DNA used as a vehicle to transmit genetic information. Co.'s primary domestic operations are in California, Florida, Maryland, and Virginia, and its primary international operations are in Hungary.
Open the XON Page at The Online Investor »
Hold (1.67 out of 4)
(ranked higher than approx. 56% of all stocks covered)
Based on Zacks ABR data;
powered by Xignite